It is well known that relapse-associated mutations in ALL are specifically selected upon by chemotherapy, exemplified by mutations in KRAS, NRAS and PTPN11, which illustrates a chemotherapy driven selection mechanism for clonal evolution7. Here, NRAS is linked to acute lymphoblastic leukemia.